NEUP: SEC Form 10-K filed by Neuphoria Therapeutics Inc.
Stocks in this Quantisnow insightHealth Care
Full content unavailable. See the original source below.
Historical context for NEUP
Across the 9 sessions after earlier NEUP headlines, the stock closed higher 4 times and lower 5 times, with a median move of 3.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.
| Session | Earlier headline | NEUP | SPY |
|---|---|---|---|
| Jul 23, 2026 | Scancell and Neuphoria Therapeutics Announce Merger Agreement and Financing | +17.7% | -1.2% |
| Jun 29, 2026 | Neuphoria Responds to the announcement made by London-listed Scancell Holdings plc | -3.7% | +1.6% |
| Dec 8, 2025 | Leading Proxy Advisory Firm ISS Recommends that Shareholders Vote the WHITE Proxy Card FOR Both of Neuphoria's Director Nominees | +6.3% | -0.3% |
| Dec 4, 2025 | Neuphoria Responds to Lynx1's Revised Indication of Interest at a Reduced Price and Premium | +1.9% | +0.1% |
| Dec 1, 2025 | Neuphoria Provides Facts, Exposes False Narratives in Response to Lynx1 Fictions | -2.9% | -0.5% |
| Nov 24, 2025 | Neuphoria Therapeutics Inc. Sends Letter to Stockholders | -0.7% | +1.5% |
Quantisnow market dataNASDAQ
NEUP
Neuphoria Therapeutics Inc.
- Market cap
- 30-day
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- Listed since
- 2021
Get push alerts for NEUP
Full NEUP profile on Quantisnow Follow NEUP and get a push notification the moment its next story breaks.
Original source Picked up and delivered by Quantisnow in real time